Publications

Export 36896 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C D E F G H I J K L [M] N O P Q R S T U V W X Y Z   [Show ALL]
A
Akçakaya, M., T. A. Basha, R. H. Chan, W. J. Manning, and R. Nezafat, "Accelerated isotropic sub-millimeter whole-heart coronary MRI: compressed sensing versus parallel imaging", Magnetic resonance in medicine, vol. 71, no. 2, pp. 815–822, 2014. Abstract
n/a
Somavat, R., H. M. H. Mohamed, Y. - K. Chung, A. E. Yousef, and S. K. Sastry, "Accelerated inactivation of Geobacillus stearothermophilus spores by ohmic heating", Journal of Food Engineering, vol. 108, pp. 69-76, 2012.
Mikolajczak, A., N. A. Sallam, R. D. Singh, T. B. Scheidl, E. J. Walsh, S. Larion, C. Huang, and J. A. Thompson, "Accelerated developmental adipogenesis programs adipose tissue dysfunction and cardiometabolic risk in offspring born to dams with metabolic dysfunction", Am J Physiol Endocrinol Metab, vol. 321, issue 5, pp. E581-E591, 2021.
Akçakaya, M., T. A. Basha, R. H. Chan, H. Rayatzadeh, K. V. Kissinger, B. Goddu, L. A. Goepfert, W. J. Manning, and R. Nezafat, "Accelerated contrast‐enhanced whole‐heart coronary MRI using low‐dimensional‐structure self‐learning and thresholding", Magnetic resonance in medicine, vol. 67, issue 5: Wiley Subscription Services, Inc., A Wiley Company, pp. 1434-1443, 2012. Abstract
n/a
Akçakaya, M., T. A. Basha, R. H. Chan, H. Rayatzadeh, K. V. Kissinger, B. Goddu, L. A. Goepfert, W. J. Manning, and R. Nezafat, "Accelerated contrast-enhanced whole-heart coronary MRI using low-dimensional-structure self-learning and thresholding", Magnetic resonance in medicine, vol. 67, no. 5: Wiley Subscription Services, Inc., A Wiley Company, pp. 1434–1443, 2012. Abstract
n/a
Akçakaya, M., T. A. Basha, R. H. Chan, H. Rayatzadeh, K. V. Kissinger, B. Goddu, L. A. Goepfert, W. J. Manning, and R. Nezafat, "Accelerated contrast-enhanced whole-heart coronary MRI using low-dimensional-structure self-learning and thresholding", Magnetic resonance in medicine, vol. 67, no. 5: Wiley Subscription Services, Inc., A Wiley Company, pp. 1434–1443, 2012. Abstract
n/a
Akçakaya, M., T. A. Basha, R. H. Chan, H. Rayatzadeh, K. V. Kissinger, B. Goddu, L. A. Goepfert, W. J. Manning, and R. Nezafat, "Accelerated contrast-enhanced whole-heart coronary MRI using low-dimensional-structure self-learning and thresholding", Magnetic resonance in medicine, vol. 67, no. 5: Wiley Subscription Services, Inc., A Wiley Company Hoboken, pp. 1434–1443, 2012. Abstract
n/a
Kwak, Y., S. Nam, M. Akçakaya, T. A. Basha, B. Goddu, W. J. Manning, V. Tarokh, and R. Nezafat, "Accelerated aortic flow assessment with compressed sensing with and without use of the sparsity of the complex difference image", Magnetic resonance in medicine, vol. 70, issue 3, pp. 851-858, 2013. Abstract
n/a
Kwak, Y., S. Nam, M. Akçakaya, T. A. Basha, B. Goddu, W. J. Manning, V. Tarokh, and R. Nezafat, "Accelerated aortic flow assessment with compressed sensing with and without use of the sparsity of the complex difference image", Magnetic resonance in medicine, vol. 70, no. 3, pp. 851–858, 2013. Abstract
n/a
M., F. M., E. S. M. M., and M. Nisreen Ezz El-Dien, "Acaricidal afficacy of Dectomax (Doramectin) against ticks and mites natural infestation among camels (Camelus dromedarius) in Egypt.", Vet. Med. J., Giza. , vol. 46, issue 4A, pp. 417-425., 1998.
El Zalabani, S. M., H. I. El-Askary, O. M. Mousa, M. Y. Issa, A. A. Zaitoun, and E. Abdel-Sattar, "Acaricidal activity of Swietenia mahogani and Swietenia macrophylla ethanolic extracts against Varroa destructor in honeybee colonies.", Experimental parasitology, vol. 130, issue 2, pp. 166-70, 2012 Feb. Abstract

The acaricidal (miticidal) activity of 90% ethanolic extracts of leaves and stem bark of Swietenia mahogani and Swietenia macrophylla were tested against Varroa destructor mite. Four concentrations were used over two different time intervals under laboratory and field conditions. In general, it was noticed that the acaricidal effect based on mortality and LC(50) of all tested extracts against the Varroa mite was concentration and time dependant. The acaricidal action against Varroa mites was relatively the least for the S. macrophylla stem bark extract at 500 ppm concentration after 48 h while it reached 100% and 95% in case of S. mahogani bark and S. macrophylla leaves, respectively. The% infestation with Varroa in colonies treated with the different extracts at various time intervals showed that the rate of infestation decreased to 0.0% after 12 days from the beginning of treatments with 500 ppm of S. mahogani leaves extract compared to 0.79% decrease after treatment with Mitac, a reference drug (60 mg/colony). The rate of infestation in case of treatments with S. mahogani bark, S. macrophylla leaves and S. macrophylla bark was decreased to 0.11%, 2.41% and 1.08%, respectively. The highest reduction was observed with S. mahogani leaves extract followed by S. mahogani bark. All the tested extracts showed less or no effect on honey bees at the different concentrations and at different bioassay times. This study suggested that the use of natural plant extracts or their products as ecofriendly biodegradable agents could be of high value for the control of Varroa mite.

Zalabani, S. E. M., H. I. El-Askary, O. M. Mousa, and M. Y. Issa, "Acaricidal activity of Swietenia mahogani and Swietenia macrophylla ethanolic extracts against Varroa destructor in honeybee colonies", Experimental Parasitology, vol. 130, pp. 166-170, 2012.
El Zalabani, S. M., H. I. El-Askary, O. M. Mousa, M. Y. Issa, A. A. Zaitoun, and E. Abdel-Sattar, "Acaricidal activity of Swietenia mahogani and Swietenia macrophylla ethanolic extracts against Varroa destructor in honeybee colonies", Experimental parasitology, vol. 130, no. 2: Academic Press, pp. 166–170, 2012. Abstract
n/a
Afify, A. M. R., F. S. Ali, M. A. Mohamed, and A. F. Turky, "Acaricidal activity of essential oils of Chamomile, Marjoram and Eucalyptus against the two-spotted spider mite, Tetranychus urticae Koch: biology and enzymes.", Acarines, vol. 3: Egyptian Society of Acarology, pp. 9-15, 2009. Abstract
n/a
Mahgoub, A. M., "Acanthamoeba Keratitis", Parasitologist United Journal, vol. 3, issue 1 & 2, pp. 9-18, 2010.
Mohamed, D., A. El-Kilany, and H. M. O. Mokhtar, "Academic Articles Recommendation Using Concept- Based Representation", Intelligent Systems Conference (IntelliSys), 3-4 September, 2020.
M.M. El-Nahass, H.A.M.Ali, M.Saadeldin, and M.Zaghllol, "AC conductivity and dielectric properties of bulk tungsten trioxide", Physica B 2012, vol. 407, issue 22, pp. 4453-4457, 2012. Abstract

AC conductivity and dielectric properties of tungsten trioxide (WO3) in a pellet form were studied in the frequency range from 42 Hz to 5 MHz with a variation of temperature in the range from 303 K to 463 K. AC conductivity, σac(ω) was found to be a function of ωs where ω is the angular frequency and s is the frequency exponent. The values of s were found to be less than unity and decrease with increasing temperature, which supports the correlated barrier hopping mechanism (CBH) as the dominant mechanism for the conduction in WO3. The dielectric constant (ε′) and dielectric loss (ε″) were measured. The Cole–Cole diagram determined complex impedance for different temperatures.

Gault, L. M., R. A. Lenz, C. W. Ritchie, A. Meier, A. A. Othman, Q. Tang, S. Berry, Y. Pritchett, and W. Z. Robieson, "ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.", Alzheimer's research & therapy, vol. 8, issue 1, pp. 44, 2016 Oct 18. AbstractWebsite

BACKGROUND: Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subjects with mild-to-moderate Alzheimer's dementia (AD). A phase 2b program was designed to evaluate a broader dose range of ABT-126 as monotherapy in subjects with mild-to-moderate AD. The program consisted of a double-blind, placebo and active controlled study of ABT-126 (dose range 25-75 mg) and an open-label extension study (75 mg).

METHODS: The randomized double-blind study enrolled 438 subjects (Mini-Mental Status Examination score of 10-24, inclusive) not currently taking acetylcholinesterase inhibitors or memantine. Subjects received 24 weeks of ABT-126 25 mg QD (n = 77), ABT-126 50 mg QD (n = 108), ABT-126 75 mg QD (n = 73), donepezil 10 mg QD (n = 76), or placebo (n = 104). The primary endpoint was the change from baseline to week 24 in the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) total score. Subjects completing the double-blind study could enroll in the 28-week open-label extension study. Adverse events (AEs) and other safety parameters were monitored in both studies.

RESULTS: A total of 367 patients (83.8 %) completed the double-blind study and 349 (79.7 %) entered the open-label study. Compared with placebo, donepezil significantly improved ADAS-Cog 11-item total scores from baseline to week 24 (-2.29 ± 0.95; one-sided P = 0.008). No ABT-126 dose demonstrated a statistically significant improvement vs placebo at week 24 in the ADAS-Cog total score: ABT-126 25 mg, -0.47 ± 0.94 (P = 0.309); ABT-126 50 mg, -0.87 ± 0.85 (P = 0.153); and ABT-126 75 mg, -1.08 ± 0.94 (P = 0.127). Rates of serious AEs and discontinuations due to AEs were similar across treatment groups. The most frequently reported AEs in both studies were constipation, fall, and headache. No clinically meaningful changes were observed in other parameters.

CONCLUSIONS: In the double-blind trial, donepezil significantly improved ADAS-Cog scores but no statistically significant improvement was seen with any ABT-126 dose. ABT-126 had an acceptable safety profile in subjects with mild-to-moderate AD in both studies.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01527916 , Registered 3 February 2012 (randomized trial). ClinicalTrials.gov NCT01676935 . Registered 29 August 2012 (open-label extension study).

El-Zawawy, M. A., "Abstraction Analysis and Certified Flow and Context Sensitive Points-to Relation for Distributed Programs", 12th International Conference Computational Science and Its Applications, ICCSA 2012, Salvador de Bahia, Brazil, June 18-21, 2012, Proceedings, Part IV, ICCSA (4), Lecture Notes in Computer Science, vol. 7336: Springer, pp. 83-99, 2012. AbstractAbstraction Analysis and Certified Flow and Context Sensitive Points-to Relation for Distributed Programs.pdf

This paper presents a new technique for pointer analysis of distributed programs executed on parallel machines with hierarchical memories. One motivation for this research is the languages whose global address space is partitioned. Examples of these languages are Fortress, X10, Titanium, Co-Array Fortran, UPC, and Chapel. These languages allow programmers to adjust threads and data layout and to write to and read from memories of other threads. The techniques presented in this paper have the form of type systems which are simply structured. The proposed technique is shown on a language which is the while langauge enriched with basic commands for pointer manipulations and also enriched with commands vital for distributed execution of programs. An abstraction analysis that for a given statement calculates the set of function abstractions that the statement may evaluate-to is introduced in this paper. The abstraction analysis is needed in the proposed pointer analysis. The mathematical soundness of all techniques presented in this paper are discussed. The soundness is proved against a new operational semantics presented in this paper. Our work has two advantages over related work. In our technique, each analysis result is associated with a correctness proof in the form of type derivation. The hierarchical memory model used in this paper is in line with the hierarchical character of concurrent parallel computers.

Saeed, D., L. Shalaby, M. Nagy, A. ElZeiny, T. M. Mostafa, M. T. Elrakaiby, M. M. Nooh, A. El-Haddad, M. Abbassi, and R. K. Aziz, Abstract LB-B19: Investigating the effect of pharmacogenetic variations on voriconazole levels in pediatric cancer patients, : AACR, 2019. Abstract
n/a
Saeed, D., L. Shalaby, M. Nagy, A. ElZeiny, T. M. Mostafa, M. T. Elrakaiby, M. M. Nooh, A. El-Haddad, M. Abbassi, and R. K. Aziz, Abstract LB-B19: Investigating the effect of pharmacogenetic variations on voriconazole levels in pediatric cancer patients, : American Association for Cancer Research, 2019. Abstract
n/a
Rivera, S., C. Vens, P. Maingon, A. S. Govaerts, E. Shash, D. Lacombe, W. Grant, and V. Grégoire, "Abstract C220: Combining novel targeted therapies and radiotherapy: A challenge to overcome.", Molecular Cancer Therapeutics, vol. 12, no. 11 Supplement: AACR, pp. C220–C220, 2013. Abstract
n/a
Tourism